APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bacterial Vaginosis OTC Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Bacterial Vaginosis OTC Drug Industry Research Report 2026

19 December 2025137 pages

Choose your research edition.

Industry ResearchBacterial Vaginosis OTC Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Bacterial Vaginosis OTC Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Bacterial Vaginosis OTC Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bacterial Vaginosis OTC Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Bacterial Vaginosis OTC Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Bacterial Vaginosis OTC Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Bacterial Vaginosis OTC Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Bacterial Vaginosis OTC Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Bacterial Vaginosis OTC Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Bacterial Vaginosis OTC Drug include Abbott, Teva, Sanofi, Pfizer, Bayer, Yunnan Baiyao, Xiuzheng, West-Ward and Starpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Bacterial Vaginosis OTC Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Bacterial Vaginosis OTC Drug Market by Company

Abbott

Teva

Sanofi

Pfizer

Bayer

Yunnan Baiyao

Xiuzheng

West-Ward

Starpharma

Piramal

Perrigo

Novel

Mission

HPGC

Galderma

Edenvridge

Alkem

Bacterial Vaginosis OTC Drug Segment by Type

Pill

Cream

Gel

Other

Bacterial Vaginosis OTC Drug Segment by Application

Pharmacy

On-line

Other

Bacterial Vaginosis OTC Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bacterial Vaginosis OTC Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bacterial Vaginosis OTC Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bacterial Vaginosis OTC Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Bacterial Vaginosis OTC Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Bacterial Vaginosis OTC Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Bacterial Vaginosis OTC Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Bacterial Vaginosis OTC Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Bacterial Vaginosis OTC Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Bacterial Vaginosis OTC Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Bacterial Vaginosis OTC Drug Revenue of Manufacturers (2021-2026) Table 9. Global Bacterial Vaginosis OTC Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Bacterial Vaginosis OTC Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Bacterial Vaginosis OTC Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Bacterial Vaginosis OTC Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Bacterial Vaginosis OTC Drug, Product Type & Application Table 14. Global Bacterial Vaginosis OTC Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Bacterial Vaginosis OTC Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abbott Company Information Table 19. Abbott Business Overview Table 20. Abbott Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Abbott Bacterial Vaginosis OTC Drug Product Portfolio Table 22. Abbott Recent Developments Table 23. Teva Company Information Table 24. Teva Business Overview Table 25. Teva Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Teva Bacterial Vaginosis OTC Drug Product Portfolio Table 27. Teva Recent Developments Table 28. Sanofi Company Information Table 29. Sanofi Business Overview Table 30. Sanofi Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Sanofi Bacterial Vaginosis OTC Drug Product Portfolio Table 32. Sanofi Recent Developments Table 33. Pfizer Company Information Table 34. Pfizer Business Overview Table 35. Pfizer Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Pfizer Bacterial Vaginosis OTC Drug Product Portfolio Table 37. Pfizer Recent Developments Table 38. Bayer Company Information Table 39. Bayer Business Overview Table 40. Bayer Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Bayer Bacterial Vaginosis OTC Drug Product Portfolio Table 42. Bayer Recent Developments Table 43. Yunnan Baiyao Company Information Table 44. Yunnan Baiyao Business Overview Table 45. Yunnan Baiyao Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Yunnan Baiyao Bacterial Vaginosis OTC Drug Product Portfolio Table 47. Yunnan Baiyao Recent Developments Table 48. Xiuzheng Company Information Table 49. Xiuzheng Business Overview Table 50. Xiuzheng Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Xiuzheng Bacterial Vaginosis OTC Drug Product Portfolio Table 52. Xiuzheng Recent Developments Table 53. West-Ward Company Information Table 54. West-Ward Business Overview Table 55. West-Ward Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. West-Ward Bacterial Vaginosis OTC Drug Product Portfolio Table 57. West-Ward Recent Developments Table 58. Starpharma Company Information Table 59. Starpharma Business Overview Table 60. Starpharma Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Starpharma Bacterial Vaginosis OTC Drug Product Portfolio Table 62. Starpharma Recent Developments Table 63. Piramal Company Information Table 64. Piramal Business Overview Table 65. Piramal Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Piramal Bacterial Vaginosis OTC Drug Product Portfolio Table 67. Piramal Recent Developments Table 68. Perrigo Company Information Table 69. Perrigo Business Overview Table 70. Perrigo Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Perrigo Bacterial Vaginosis OTC Drug Product Portfolio Table 72. Perrigo Recent Developments Table 73. Novel Company Information Table 74. Novel Business Overview Table 75. Novel Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Novel Bacterial Vaginosis OTC Drug Product Portfolio Table 77. Novel Recent Developments Table 78. Mission Company Information Table 79. Mission Business Overview Table 80. Mission Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Mission Bacterial Vaginosis OTC Drug Product Portfolio Table 82. Mission Recent Developments Table 83. HPGC Company Information Table 84. HPGC Business Overview Table 85. HPGC Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. HPGC Bacterial Vaginosis OTC Drug Product Portfolio Table 87. HPGC Recent Developments Table 88. Galderma Company Information Table 89. Galderma Business Overview Table 90. Galderma Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Galderma Bacterial Vaginosis OTC Drug Product Portfolio Table 92. Galderma Recent Developments Table 93. Edenvridge Company Information Table 94. Edenvridge Business Overview Table 95. Edenvridge Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Edenvridge Bacterial Vaginosis OTC Drug Product Portfolio Table 97. Edenvridge Recent Developments Table 98. Alkem Company Information Table 99. Alkem Business Overview Table 100. Alkem Bacterial Vaginosis OTC Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Alkem Bacterial Vaginosis OTC Drug Product Portfolio Table 102. Alkem Recent Developments Table 103. Global Bacterial Vaginosis OTC Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Bacterial Vaginosis OTC Drug Sales by Region (2021-2026) & (K Units) Table 105. Global Bacterial Vaginosis OTC Drug Sales Market Share by Region (2021-2026) Table 106. Global Bacterial Vaginosis OTC Drug Sales by Region (2027-2032) & (K Units) Table 107. Global Bacterial Vaginosis OTC Drug Sales Market Share by Region (2027-2032) Table 108. Global Bacterial Vaginosis OTC Drug Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region (2021-2026) Table 110. Global Bacterial Vaginosis OTC Drug Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Region (2027-2032) Table 112. North America Bacterial Vaginosis OTC Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 114. North America Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 115. North America Bacterial Vaginosis OTC Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Bacterial Vaginosis OTC Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Bacterial Vaginosis OTC Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 119. Europe Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 120. Europe Bacterial Vaginosis OTC Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Bacterial Vaginosis OTC Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Bacterial Vaginosis OTC Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 129. South America Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 130. South America Bacterial Vaginosis OTC Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Bacterial Vaginosis OTC Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Bacterial Vaginosis OTC Drug Sales by Type (2021-2026) & (K Units) Table 138. Global Bacterial Vaginosis OTC Drug Sales by Type (2027-2032) & (K Units) Table 139. Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2021-2026) Table 140. Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2027-2032) Table 141. Global Bacterial Vaginosis OTC Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Bacterial Vaginosis OTC Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2021-2026) Table 144. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2027-2032) Table 145. Global Bacterial Vaginosis OTC Drug Price by Type (2021-2026) & (US$/Unit) Table 146. Global Bacterial Vaginosis OTC Drug Price by Type (2027-2032) & (US$/Unit) Table 147. Global Bacterial Vaginosis OTC Drug Sales by Application (2021-2026) & (K Units) Table 148. Global Bacterial Vaginosis OTC Drug Sales by Application (2027-2032) & (K Units) Table 149. Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2021-2026) Table 150. Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2027-2032) Table 151. Global Bacterial Vaginosis OTC Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Bacterial Vaginosis OTC Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2021-2026) Table 154. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2027-2032) Table 155. Global Bacterial Vaginosis OTC Drug Price by Application (2021-2026) & (US$/Unit) Table 156. Global Bacterial Vaginosis OTC Drug Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Bacterial Vaginosis OTC Drug Distributors List Table 160. Bacterial Vaginosis OTC Drug Customers List Table 161. Bacterial Vaginosis OTC Drug Industry Trends Table 162. Bacterial Vaginosis OTC Drug Industry Drivers Table 163. Bacterial Vaginosis OTC Drug Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Bacterial Vaginosis OTC Drug Product Image Figure 5. Global Bacterial Vaginosis OTC Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Bacterial Vaginosis OTC Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Bacterial Vaginosis OTC Drug Sales (2021-2032) & (K Units) Figure 8. Global Bacterial Vaginosis OTC Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Pill Product Image Figure 10. Cream Product Image Figure 11. Gel Product Image Figure 12. Other Product Image Figure 13. Pharmacy Product Image Figure 14. On-line Product Image Figure 15. Other Product Image Figure 16. Global Bacterial Vaginosis OTC Drug Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Bacterial Vaginosis OTC Drug, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Bacterial Vaginosis OTC Drug Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Bacterial Vaginosis OTC Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Bacterial Vaginosis OTC Drug Sales by Region in 2025 Figure 22. Global Bacterial Vaginosis OTC Drug Revenue by Region in 2025 Figure 23. North America Bacterial Vaginosis OTC Drug Market Size by Country in 2025 Figure 24. North America Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 25. North America Bacterial Vaginosis OTC Drug Revenue Market Share by Country (2021-2032) Figure 26. United States Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Bacterial Vaginosis OTC Drug Market Size by Country in 2025 Figure 29. Europe Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 30. Europe Bacterial Vaginosis OTC Drug Revenue Market Share by Country (2021-2032) Figure 31. Germany Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Asia Pacific Bacterial Vaginosis OTC Drug Market Size by Country in 2025 Figure 37. Asia Pacific Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 38. Asia Pacific Bacterial Vaginosis OTC Drug Revenue Market Share by Country (2021-2032) Figure 39. China Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Japan Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. South Korea Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. India Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Australia Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. China Taiwan Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South America Bacterial Vaginosis OTC Drug Market Size by Country in 2025 Figure 48. South America Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 49. South America Bacterial Vaginosis OTC Drug Revenue Market Share by Country (2021-2032) Figure 50. Mexico Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Brazil Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Argentina Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Bacterial Vaginosis OTC Drug Market Size by Country in 2025 Figure 54. Middle East and Africa Bacterial Vaginosis OTC Drug Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Bacterial Vaginosis OTC Drug Revenue Market Share by Country (2021-2032) Figure 56. Turkey Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Bacterial Vaginosis OTC Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2021-2032) Figure 60. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2021-2032) Figure 61. Global Bacterial Vaginosis OTC Drug Price (US$/Unit) by Type (2021-2032) Figure 62. Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2021-2032) Figure 63. Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2021-2032) Figure 64. Global Bacterial Vaginosis OTC Drug Price (US$/Unit) by Application (2021-2032) Figure 65. Bacterial Vaginosis OTC Drug Value Chain Figure 66. Bacterial Vaginosis OTC Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Bacterial Vaginosis OTC Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Pill
  • Cream
  • Gel
  • Other
Applications
  • Pharmacy
  • On-line
  • Other
Companies covered
  • Abbott
  • Teva
  • Sanofi
  • Pfizer
  • Bayer
  • Yunnan Baiyao
  • Xiuzheng
  • West-Ward
  • Starpharma
  • Piramal
  • Perrigo
  • Novel
  • Mission
  • HPGC
  • Galderma
  • Edenvridge
  • Alkem

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Bacterial Vaginosis OTC Drug Market Size (2021-2032)
  4. 2.2.2 Global Bacterial Vaginosis OTC Drug Sales (2021-2032)
  5. 2.2.3 Global Bacterial Vaginosis OTC Drug Market Average Price (2021-2032)
  6. 2.3 Bacterial Vaginosis OTC Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Pill
  9. 2.3.3 Cream
  10. 2.3.4 Gel
  11. 2.3.5 Other
  12. 2.4 Bacterial Vaginosis OTC Drug by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Pharmacy
  15. 2.4.3 On-line
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Bacterial Vaginosis OTC Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Bacterial Vaginosis OTC Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Bacterial Vaginosis OTC Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Bacterial Vaginosis OTC Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Bacterial Vaginosis OTC Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Bacterial Vaginosis OTC Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Bacterial Vaginosis OTC Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Bacterial Vaginosis OTC Drug, Established Date
  9. 3.9 Global Bacterial Vaginosis OTC Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abbott
  2. 4.1.1 Abbott Company Information
  3. 4.1.2 Abbott Business Overview
  4. 4.1.3 Abbott Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abbott Bacterial Vaginosis OTC Drug Product Portfolio
  6. 4.1.5 Abbott Recent Developments
  7. 4.2 Teva
  8. 4.2.1 Teva Company Information
  9. 4.2.2 Teva Business Overview
  10. 4.2.3 Teva Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Teva Bacterial Vaginosis OTC Drug Product Portfolio
  12. 4.2.5 Teva Recent Developments
  13. 4.3 Sanofi
  14. 4.3.1 Sanofi Company Information
  15. 4.3.2 Sanofi Business Overview
  16. 4.3.3 Sanofi Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sanofi Bacterial Vaginosis OTC Drug Product Portfolio
  18. 4.3.5 Sanofi Recent Developments
  19. 4.4 Pfizer
  20. 4.4.1 Pfizer Company Information
  21. 4.4.2 Pfizer Business Overview
  22. 4.4.3 Pfizer Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Bacterial Vaginosis OTC Drug Product Portfolio
  24. 4.4.5 Pfizer Recent Developments
  25. 4.5 Bayer
  26. 4.5.1 Bayer Company Information
  27. 4.5.2 Bayer Business Overview
  28. 4.5.3 Bayer Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Bayer Bacterial Vaginosis OTC Drug Product Portfolio
  30. 4.5.5 Bayer Recent Developments
  31. 4.6 Yunnan Baiyao
  32. 4.6.1 Yunnan Baiyao Company Information
  33. 4.6.2 Yunnan Baiyao Business Overview
  34. 4.6.3 Yunnan Baiyao Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Yunnan Baiyao Bacterial Vaginosis OTC Drug Product Portfolio
  36. 4.6.5 Yunnan Baiyao Recent Developments
  37. 4.7 Xiuzheng
  38. 4.7.1 Xiuzheng Company Information
  39. 4.7.2 Xiuzheng Business Overview
  40. 4.7.3 Xiuzheng Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Xiuzheng Bacterial Vaginosis OTC Drug Product Portfolio
  42. 4.7.5 Xiuzheng Recent Developments
  43. 4.8 West-Ward
  44. 4.8.1 West-Ward Company Information
  45. 4.8.2 West-Ward Business Overview
  46. 4.8.3 West-Ward Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 West-Ward Bacterial Vaginosis OTC Drug Product Portfolio
  48. 4.8.5 West-Ward Recent Developments
  49. 4.9 Starpharma
  50. 4.9.1 Starpharma Company Information
  51. 4.9.2 Starpharma Business Overview
  52. 4.9.3 Starpharma Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Starpharma Bacterial Vaginosis OTC Drug Product Portfolio
  54. 4.9.5 Starpharma Recent Developments
  55. 4.10 Piramal
  56. 4.10.1 Piramal Company Information
  57. 4.10.2 Piramal Business Overview
  58. 4.10.3 Piramal Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Piramal Bacterial Vaginosis OTC Drug Product Portfolio
  60. 4.10.5 Piramal Recent Developments
  61. 4.11 Perrigo
  62. 4.11.1 Perrigo Company Information
  63. 4.11.2 Perrigo Business Overview
  64. 4.11.3 Perrigo Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Perrigo Bacterial Vaginosis OTC Drug Product Portfolio
  66. 4.11.5 Perrigo Recent Developments
  67. 4.12 Novel
  68. 4.12.1 Novel Company Information
  69. 4.12.2 Novel Business Overview
  70. 4.12.3 Novel Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Novel Bacterial Vaginosis OTC Drug Product Portfolio
  72. 4.12.5 Novel Recent Developments
  73. 4.13 Mission
  74. 4.13.1 Mission Company Information
  75. 4.13.2 Mission Business Overview
  76. 4.13.3 Mission Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Mission Bacterial Vaginosis OTC Drug Product Portfolio
  78. 4.13.5 Mission Recent Developments
  79. 4.14 HPGC
  80. 4.14.1 HPGC Company Information
  81. 4.14.2 HPGC Business Overview
  82. 4.14.3 HPGC Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 HPGC Bacterial Vaginosis OTC Drug Product Portfolio
  84. 4.14.5 HPGC Recent Developments
  85. 4.15 Galderma
  86. 4.15.1 Galderma Company Information
  87. 4.15.2 Galderma Business Overview
  88. 4.15.3 Galderma Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Galderma Bacterial Vaginosis OTC Drug Product Portfolio
  90. 4.15.5 Galderma Recent Developments
  91. 4.16 Edenvridge
  92. 4.16.1 Edenvridge Company Information
  93. 4.16.2 Edenvridge Business Overview
  94. 4.16.3 Edenvridge Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Edenvridge Bacterial Vaginosis OTC Drug Product Portfolio
  96. 4.16.5 Edenvridge Recent Developments
  97. 4.17 Alkem
  98. 4.17.1 Alkem Company Information
  99. 4.17.2 Alkem Business Overview
  100. 4.17.3 Alkem Bacterial Vaginosis OTC Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Alkem Bacterial Vaginosis OTC Drug Product Portfolio
  102. 4.17.5 Alkem Recent Developments
5 Global Bacterial Vaginosis OTC Drug Market Scenario by Region
  1. 5.1 Global Bacterial Vaginosis OTC Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Bacterial Vaginosis OTC Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Bacterial Vaginosis OTC Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Bacterial Vaginosis OTC Drug Sales by Region: 2027-2032
  5. 5.3 Global Bacterial Vaginosis OTC Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Bacterial Vaginosis OTC Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Bacterial Vaginosis OTC Drug Revenue by Region: 2027-2032
  8. 5.4 North America Bacterial Vaginosis OTC Drug Market Facts & Figures by Country
  9. 5.4.1 North America Bacterial Vaginosis OTC Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Bacterial Vaginosis OTC Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Bacterial Vaginosis OTC Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Bacterial Vaginosis OTC Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Bacterial Vaginosis OTC Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Bacterial Vaginosis OTC Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Bacterial Vaginosis OTC Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Bacterial Vaginosis OTC Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Bacterial Vaginosis OTC Drug Market Facts & Figures by Country
  35. 5.7.1 South America Bacterial Vaginosis OTC Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Bacterial Vaginosis OTC Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Bacterial Vaginosis OTC Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Bacterial Vaginosis OTC Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Bacterial Vaginosis OTC Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Bacterial Vaginosis OTC Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Bacterial Vaginosis OTC Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Bacterial Vaginosis OTC Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Bacterial Vaginosis OTC Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Bacterial Vaginosis OTC Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Bacterial Vaginosis OTC Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Bacterial Vaginosis OTC Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Bacterial Vaginosis OTC Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Bacterial Vaginosis OTC Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Bacterial Vaginosis OTC Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Bacterial Vaginosis OTC Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Bacterial Vaginosis OTC Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Bacterial Vaginosis OTC Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Bacterial Vaginosis OTC Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Bacterial Vaginosis OTC Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Bacterial Vaginosis OTC Drug Value Chain Analysis
  2. 8.1.1 Bacterial Vaginosis OTC Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Bacterial Vaginosis OTC Drug Production Mode & Process
  5. 8.2 Bacterial Vaginosis OTC Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Bacterial Vaginosis OTC Drug Distributors
  8. 8.2.3 Bacterial Vaginosis OTC Drug Customers
9 Global Bacterial Vaginosis OTC Drug Analyzing Market Dynamics
  1. 9.1 Bacterial Vaginosis OTC Drug Industry Trends
  2. 9.2 Bacterial Vaginosis OTC Drug Industry Drivers
  3. 9.3 Bacterial Vaginosis OTC Drug Industry Opportunities and Challenges
  4. 9.4 Bacterial Vaginosis OTC Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst